Navigation Links
Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
Date:4/10/2013

JUPITER, Fla., April 10, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb , will speak at the Advanced Biofuels Leadership Conference in Washington, DC, during its conference session: Hot Technologies & Products, at 2:30 p.m. EDT on April 17, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

The Advanced Biofuels Leadership Conference has become one of the largest gatherings of CEOs, senior executives, strategic partners, financiers, equity analysts, policymakers and industry suppliers in the Advanced Biofuels & Renewable Chemicals and Biomaterials industries in North America. The conference brings these leaders together to showcase leading companies, technologies and business strategies, and to discuss crucial technologies, partnership, financial strategies, and energy, agricultural, tax and trade policy issues, that together are charting the future of the Biofuels & Renewable Chemicals and Biomaterials industries in the US and Internationally.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Present At World Biofuels Markets
2. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
3. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
4. 12th U.S. Patent Issued To Dyadic International
5. Dyadic International Reports 2012 Third Quarter Financial Results
6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
7. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
8. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
9. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
10. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
11. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/4/2016)... - New FDA action date of July 22, ... July 22, 2016   --> - ...   - Lifitegrast has the potential to be the ... signs and symptoms of dry eye disease in adults ... product approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... 2016  CytoSorbents Corporation (NASDAQ: CTSO ), ... CytoSorb® blood filter to treat deadly inflammation in ... announced that CEO Dr. Phillip Chan , ... Group,s 2016 Disruptive Growth & Healthcare Conference, providing ... Conference Presentation Details: Where: Convene Conference ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") ... products in China , today announced ... received on February 4, 2016 a preliminary non-binding proposal ... of PKU V-Ming ( Shanghai ) Investment ... Development ( Shenzhen ) Fund Management Co., ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
Breaking Biology News(10 mins):